Biopharma in the Time of COVID-19

As biopharma companies adjust to a new era of change and uncertainty, Business Talent Group’s marketplace of independent experts, consultants, project managers, and executives are here to help. Our fast, flexible, and low-risk source of skills and expertise can be a tremendous asset to help you fuel your critical initiatives, pivot faster, and cover any skills or capacity gaps you may have.

BTG Talent Facts

3,750+ highly specialized life science talent

6,000+ experienced project, program, and change managers

Sample BTG Biopharma Talent

Quality and Regulatory Executive

Experienced at managing FDA observations, product manufacturing, and releases in the vaccines space

Product Commercialization Executive

With deep experience developing and launching vaccines and antiviral therapies and diagnostics

Supply Chain Executive

Advises global regulatory agencies on pharmaceutical industry procurement and logistics

Manufacturing Operations Leader

Skilled at rapidly scaling up Lean manufacturing and distribution programs globally within the life science industry

Vaccinologist and Public Health Expert

Works with leading NGOs and pharma companies to scale manufacturing and develop frameworks to monitor adverse events (AEFI)

BTG is here to help with ongoing work and urgent priorities:

Pandemic / epidemic response

Operations and supply chain

Interim leadership

Pharmacovigilence

Project management

Research and development

Vaccine development support across business functions

Crisis management

Post-merger integration

Regulatory and market access

And more

We're here to help

Contact us today to discuss your talent needs.

Contact Us
Previous Flipbook
Life Science in the Time of COVID-19
Life Science in the Time of COVID-19

Get on-demand talent to help you fuel your critical initiatives, pivot faster, and cover any skills or capa...

Next Article
Reorganizing the Global Pharmacovigilance Function
Reorganizing the Global Pharmacovigilance Function

An F200 pharma company was reevaluating the operating model of its global drug safety and pharmacovigilance...